Fig 1.
Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), randomized controlled trial (RCT).
Fig 2.
Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n
= 42). Error bars represent 95% confidence intervals. Generalized estimating equations were used to test statistical significance of differences within and between treatment groups. Models were adjusted for age, BMI and baseline aerobic exercise level. Each week was compared to baseline using unadjusted multiple comparisons. *Indicates statistically significantly different from baseline at p ≤ 0.03. Week 0 indicates baseline. Week 18 indicates the end of chemotherapy. Abbreviations: Docosahexaenoic acid (DHA), body mass index (BMI).
Fig 3.
Weekly resistance training frequency over time for the DHA and placebo groups combined (n
= 42). Error bars represent 95% confidence intervals. Generalized estimating equations were used to test statistical significance of differences within and between treatment groups. Models were adjusted for age, BMI and baseline resistance training exercise frequency. Each week was compared to baseline using unadjusted multiple comparisons. *Indicates statistically significantly different from baseline at p ≤ 0.03. Week 0 indicates baseline. Week 18 indicates the end of cycle 6. Abbreviations: Docosahexaenoic acid (DHA), body mass index (BMI).
Table 1.
Participant demographic and clinical characteristics.
Table 2.
Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups.
Table 3.
Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic exercise recommendation on average during chemotherapy.
Table 4.
Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance training exercise recommendation on average during chemotherapy.